Short description
A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions.
Description
A-Alpha Bio is a provider of cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio utilizes its proprietary AlphaSeq technology to map protein-protein interactions at a high scale and resolution. This technology can identify and quantify interactions between thousands of protein pairs simultaneously. By providing detailed maps of protein interactions, A-Alpha Bio aids in the identification of potential drug targets and the understanding of disease mechanisms. This can significantly streamline the process of discovering new therapeutics.
A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck.
Last funding
Nopepepe
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Seattle, Washington, United States, North America
Founded on
January 1, 2017
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$7890 - 12340
Sign in for full access
Investors
Absolutely Noaccess, No Way, Noaccess, Uh Ohhhh, Noaccess, Absolutely Noaccess, Noway Youcantaccess, Absolutely Noaccess, Uh Ohhhh, Uh Ohhhh, Uh Ohhhh, Cannot Access, Blurry Noaccess
Sign in for full access
Founders
David Younger, Randolph Lopez